Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
AIDS and Behavior
Published in: AIDS and Behavior 12/2020

01-12-2020 | Human Immunodeficiency Virus | Original Paper

Adherence to Pre-exposure Prophylaxis in Black Men Who Have Sex with Men and Transgender Women in a Community Setting in Harlem, NY

Authors: P. W. Colson, J. Franks, Y. Wu, F. S. Winterhalter, J. Knox, H. Ortega, W. M. El-Sadr, Y. Hirsch-Moverman

Published in: AIDS and Behavior | Issue 12/2020

Login to get access

Abstract

While oral pre-exposure prophylaxis (PrEP) has proven efficacious for HIV prevention, consistent use is necessary to achieve its intended impact. We compared effectiveness of enhanced PrEP (enPrEP) adherence support to standard of care (sPrEP) among Black MSM and TGW attending a community clinic in Harlem, NY. EnPrEP included peer navigation, in-person/online support groups, and SMS messages. Self-reported adherence over previous 30 days, collected in quarterly interviews, was defined as ≥ 57%. Crude and adjusted analyses examined factors associated with adherence. A total of 204 participants were enrolled and randomized; 35% were lost to follow-up. PrEP adherence was 30% at 12-months; no intervention effect was observed (p = 0.69). Multivariable regression analysis found that lower adherence was associated with low education and depressive symptoms. We found that an enhanced adherence intervention did not improve PrEP adherence. Findings point to the need for innovative methods to improve PrEP adherence among Black MSM and TGW.
Clinical Trial Registration NCT02167386, June 19, 2014
Appendix
Available only for authorised users
Literature
1.
2.
3.
4.
Hess KL, Hu X, Lansky A, Mermin J, Hall HI. Lifetime risk of a diagnosis of HIV infection in the United States. Ann Epidemiol. 2017;27(4):238–43.PubMedPubMedCentral
5.
6.
Baral SD, Poteat T, Stromdahl S, Wirtz AL, Guadamuz TE, Beyrer C. Worldwide burden of HIV in transgender women: a systematic review and meta-analysis. Lancet Infect Dis. 2013;13(3):214–22.PubMed
7.
Becasen JS, Denard CL, Mullins MM, Higa DH, Sipe TA. Estimating the prevalence of HIV and sexual behaviors among the US transgender population: a systematic review and meta-analysis, 2006–2017. Am J Public Health. 2019;2018:11–8.
8.
9.
Caceres CF, Borquez A, Klausner JD, Baggaley R, Beyrer C. Implementation of pre-exposure prophylaxis for human immunodeficiency virus infection: progress and emerging issues in research and policy. J Int AIDS Soc. 2016;19(Suppl 6):21108.PubMedPubMedCentral
10.
Cohen SE, Vittinghoff E, Bacon O, et al. High interest in preexposure prophylaxis among men who have sex with men at risk for HIV infection: baseline data from the US PrEP demonstration project. J Acquir Immune Defic Syndr. 2015;68(4):439–48.PubMedPubMedCentral
11.
Haberer JE, Bangsberg DR, Baeten JM, et al. Defining success with HIV pre-exposure prophylaxis: a prevention-effective adherence paradigm. AIDS. 2015;29(11):1277–85.PubMedPubMedCentral
12.
Jenness SM, Maloney KM, Smith DK, et al. Addressing gaps in HIV preexposure prophylaxis care to reduce racial disparities in HIV incidence in the United States. Am J Epidemiol. 2019;188(4):743–52.PubMed
13.
Mimiaga MJ, Closson EF, Kothary V, Mitty JA. Sexual partnerships and considerations for HIV antiretroviral pre-exposure prophylaxis utilization among high-risk substance using men who have sex with men. Arch Sex Behav. 2014;43(1):99–106.PubMedPubMedCentral
14.
Riddell JT, Cohn JA. Reaching high-risk patients for HIV preexposure prophylaxis. JAMA. 2016;316(2):211–2.PubMed
15.
Wu H, Mendoza MC, Huang YA, Hayes T, Smith DK, Hoover KW. Uptake of HIV preexposure prophylaxis among commercially insured persons-United States, 2010–2014. Clin Infect Dis. 2017;64(2):144–9.PubMed
16.
United States Public Health Service. Preexposure prophylaxis for the prevention of HIV infection in the United States 2014: a clinical practice guideline. Washington: Centers for Disease Control and Prevention, Department of Health and Human Services; 2014.
17.
Sullivan PS, Giler RM, Mouhanna F, et al. Trends in the use of oral emtricitabine/tenofovir disoproxil fumarate for pre-exposure prophylaxis against HIV infection, United States, 2012–2017. Ann Epidemiol. 2018;28(12):833–40.PubMedPubMedCentral
18.
Misra K, Udeagu CC. Disparities in awareness of HIV postexposure and preexposure prophylaxis among notified partners of HIV-positive individuals, New York City 2015–2017. J Acquir Immune Defic Syndr. 2017;76(2):132–40.PubMed
19.
Siegler AJ, Mouhanna F, Giler RM, et al. The prevalence of pre-exposure prophylaxis use and the pre-exposure prophylaxis-to-need ratio in the fourth quarter of 2017, United States. Ann Epidemiol. 2018;28(12):841–9.PubMedPubMedCentral
20.
Harris NS, Johnson AS, Huang YA, et al. Vital signs: status of human immunodeficiency virus testing, viral suppression, and HIV preexposure prophylaxis - United States, 2013–2018. MMWR Morb Mortal Wkly Rep. 2019;68(48):1117–23.PubMedPubMedCentral
21.
Kelley CF, Kahle E, Siegler A, et al. Applying a PrEP continuum of care for men who have sex with men in Atlanta. Georgia Clin Infect Dis. 2015;61(10):1590–7.PubMed
22.
Shover CL, Shoptaw S, Javanbakht M, et al. Mind the gaps: prescription coverage and HIV incidence among patients receiving pre-exposure prophylaxis from a large federally qualified health center in Los Angeles, CA. AIDS Behav. 2019;23:2730–40.PubMedPubMedCentral
23.
Scott HM, Spinelli M, Vittinghoff E, et al. Racial/ethnic and HIV risk category disparities in preexposure prophylaxis discontinuation among patients in publicly funded primary care clinics. AIDS. 2019;33(14):2189–95.PubMed
24.
Amico KR. Adherence to preexposure chemoprophylaxis: the behavioral bridge from efficacy to effectiveness. Curr Opin HIV AIDS. 2012;7(6):542–8.PubMed
25.
Serota DP, Rosenberg ES, Lockard AM, et al. Beyond the biomedical: preexposure prophylaxis failures in a cohort of young black men who have sex with men in Atlanta, Georgia. Clin Infect Dis. 2018;67(6):965–70.PubMedPubMedCentral
26.
Spinelli MA, Scott HM, Vittinghoff E, et al. Missed visits associated with future preexposure prophylaxis (PrEP) discontinuation among PrEP Users in a municipal primary care health network. Open Forum Infect Dis. 2019;6(4):ofz101.PubMedPubMedCentral
27.
Ayala G, Makofane K, Santos GM, et al. Access to basic HIV-related services and PrEP acceptability among men who have sex with men worldwide: barriers, facilitators, and implications for combination prevention. J Sex Transm Dis. 2013;2013:953123.PubMedPubMedCentral
28.
Koechlin FM, Fonner VA, Dalglish SL, et al. Values and preferences on the use of oral pre-exposure prophylaxis (PrEP) for HIV prevention among multiple populations: a systematic review of the literature. AIDS Behav. 2017;21(5):1325–35.PubMed
29.
Sevelius JM, Deutsch MB, Grant R. The future of PrEP among transgender women: the critical role of gender affirmation in research and clinical practices. J Int AIDS Soc. 2016;19(Suppl 6):21105.PubMedPubMedCentral
30.
Grant JM, Mottet LA, Tanis J, Harrison J, Herman JL, Keisling M. Injustice at every turn: a report of the National Transgender Discrimination Survey. Washington: National Gay and Lesbian Task Force and National Center for Transgender Equality; 2011.
31.
Bauer GR, Hammond R, Travers R, Kaay M, Hohenadel KM, Boyce M. "I don't think this is theoretical; this is our lives": how erasure impacts health care for transgender people. J Assoc Nurses AIDS Care. 2009;20(5):348–61.PubMed
32.
Khalili J, Leung LB, Diamant AL. Finding the perfect doctor: identifying lesbian, gay, bisexual, and transgender-competent physicians. Am J Public Health. 2015;105(6):1114–9.PubMedPubMedCentral
33.
34.
Centers for Disease Control and Prevention. Recommendations for HIV prevention with adults and adolescents with HIV in the United States, 2014. Centers for Disease Control and Prevention, Health Resources and Services Administration, National Institutes of Health, American Academy of HIV Medicine, Association of Nurses in AIDS Care, International Association of Providers of AIDS Care, the National Minority AIDS Council, and Urban Coalition for HIV/AIDS Prevention Services. 2014.
35.
Hall HI, Song R, Tang T, et al. HIV trends in the United States: diagnoses and estimated incidence. JMIR Public Health Surveill. 2017;3(1):e8.PubMedPubMedCentral
36.
Kangovi S, Mitra N, Grande D, Huo H, Smith RA, Long JA. Community health worker support for disadvantaged patients with multiple chronic diseases: a randomized clinical trial. Am J Public Health. 2017;107(10):1660–7.PubMedPubMedCentral
37.
Ramchand R, Ahluwalia SC, Xenakis L, Apaydin E, Raaen L, Grimm G. A systematic review of peer-supported interventions for health promotion and disease prevention. Prev Med. 2017;101:156–70.PubMed
38.
Bateganya MH, Amanyeiwe U, Roxo U, Dong M. Impact of support groups for people living with HIV on clinical outcomes: a systematic review of the literature. J Acquir Immune Defic Syndr. 2015;68(Suppl 3):S368–S374374.PubMedPubMedCentral
39.
Amico KR. Evidence for technology interventions to promote ART adherence in adult populations: a review of the literature 2012–2015. Curr HIV/AIDS Rep. 2015;12(4):441–50.PubMedPubMedCentral
40.
Gaysynsky A, Romansky-Poulin K, Arpadi S. "My YAP Family": analysis of a Facebook Group for young adults living with HIV. AIDS Behav. 2015;19(6):947–62.PubMed
41.
Simoni JM, Ronen K, Aunon FM. Health behavior theory to enhance eHealth intervention research in HIV: rationale and review. Curr HIV/AIDS Rep. 2018;15(6):423–30.PubMedPubMedCentral
42.
Fuchs JD, Stojanovski K, Vittinghoff E, et al. A mobile health strategy to support adherence to antiretroviral preexposure prophylaxis. AIDS Pat Care STDS. 2018;32(3):104–11.
43.
Lester RT, Ritvo P, Mills EJ, et al. Effects of a mobile phone short message service on antiretroviral treatment adherence in Kenya (WelTel Kenya1): a randomised trial. Lancet. 2010;376(9755):1838–45.PubMed
44.
Moore DJ, Jain S, Dube MP, et al. Randomized controlled trial of daily text messages to support adherence to preexposure prophylaxis in individuals at risk for human immunodeficiency virus: the TAPIR Study. Clin Infect Dis. 2018;66(10):1566–72.PubMed
45.
46.
Garcia J, Colson PW, Parker C, Hirsch JS. Passing the baton: Community-based ethnography to design a randomized clinical trial on the effectiveness of oral pre-exposure prophylaxis for HIV prevention among Black men who have sex with men. Contemp Clin Trials. 2015;45(Pt B):244–51.PubMedPubMedCentral
47.
Wilson IB, Lee Y, Michaud J, Fowler FJ Jr, Rogers WH. Validation of a new three-item self-report measure for medication adherence. AIDS Behav. 2016;20(11):2700–8.PubMedPubMedCentral
48.
Anderson PL, Liu AY, Castillo-Mancilla JR, et al. Intracellular tenofovir-diphosphate and emtricitabine-triphosphate in dried blood spots following directly observed therapy. Antimicrob Agents Chemother. 2018;62(1):e01710.PubMed
49.
Chan PA, Mena L, Patel R, et al. Retention in care outcomes for HIV pre-exposure prophylaxis implementation programmes among men who have sex with men in three US cities. J Int AIDS Soc. 2016;19(1):20903.PubMedPubMedCentral
50.
Colson PW, Hirsch-Moverman Y, Franks J, Ortega H, El-Sadr WM. PrEP knowledge & attitudes, perceived benefits and barriers. Columbia: ICAP, Columbia University; 2014.
51.
Simpson DD, Joe GW, Knight K, Rowan-Szal GA, Gray JS. Texas Christian University (TCU) short forms for assessing client needs and functioning in addiction treatment. J Offender Rehabil. 2012;51(1–2):34–56.PubMedPubMedCentral
52.
Saunders JB, Aasland OG, Babor TF, de la Fuente JR, Grant M. Development of the alcohol use disorders identification test (AUDIT): WHO collaborative project on early detection of persons with harmful alcohol consumption–II. Addiction. 1993;88(6):791–804.PubMed
53.
Radloff LS. The CES-D Scale: a self-report depression scale for research in the general population. Appl Psychol Meas. 1977;1(3):385–401.
54.
55.
Garcia J, Parker C, Parker RG, Wilson PA, Philbin M, Hirsch JS. Psychosocial implications of homophobia and HIV stigma in social support networks: insights for high-impact HIV prevention among black men who have sex with men. Health Educ Behav. 2016;43(2):217–25.PubMed
56.
Garcia J, Parker C, Parker RG, Wilson PA, Philbin MM, Hirsch JS. "You're really gonna kick us all out?" Sustaining safe spaces for community-based HIV prevention and control among black men who have sex with men. PLoS ONE. 2015;10(10):e0141326.PubMedPubMedCentral
57.
Parker CM, Parker RG, Philbin MM, Hirsch JS. The impact of urban US policing practices on black men who have sex with men's HIV vulnerability: ethnographic findings and a conceptual model for future research. J Urban Health. 2018;95(2):171–8.PubMedPubMedCentral
58.
Alsabbagh MH, Lemstra M, Eurich D, et al. Socioeconomic status and nonadherence to antihypertensive drugs: a systematic review and meta-analysis. Value Health. 2014;17(2):288–96.PubMed
59.
Falagas ME, Zarkadoulia EA, Pliatsika PA, Panos G. Socioeconomic status (SES) as a determinant of adherence to treatment in HIV infected patients: a systematic review of the literature. Retrovirology. 2008;5:13.PubMedPubMedCentral
60.
Marcus JL, Hurley LB, Hare CB, et al. Preexposure prophylaxis for HIV prevention in a large integrated health care system: adherence, renal safety, and discontinuation. J Acquir Immune Defic Syndr. 2016;73(5):540–6.PubMedPubMedCentral
61.
Hosek SG, Rudy B, Landovitz R, et al. An HIV preexposure prophylaxis demonstration project and safety study for young MSM. J Acquir Immune Defic Syndr. 2017;74(1):21–9.PubMedPubMedCentral
62.
Kaaya S, Eustache E, Lapidos-Salaiz I, Musisi S, Psaros C, Wissow L. Grand challenges: improving HIV treatment outcomes by integrating interventions for co-morbid mental illness. PLoS Med. 2013;10(5):e1001447.PubMedPubMedCentral
63.
Patel V, Belkin GS, Chockalingam A, Cooper J, Saxena S, Unutzer J. Grand challenges: integrating mental health services into priority health care platforms. PLoS Med. 2013;10(5):e1001448.PubMedPubMedCentral
64.
Golub SA, Pena S, Hilley A, Pachankis J, Radix A. Brief behavioral intervention increases PrEP drug levels in a real-world setting. Conference on retroviruses and opportunistic infections; Seattle, WA. abs 965. 2017.
65.
Wheeler DP, Fields SD, Beauchamp G, et al. Pre-exposure prophylaxis initiation and adherence among Black men who have sex with men (MSM) in three US cities: results from the HPTN 073 study. J Int AIDS Soc. 2019;22(2):e25223.PubMedPubMedCentral
66.
Remy L, Enriquez M. Behavioral interventions to enhance PrEP uptake among black men who have sex with men: a review. J Assoc Nurses AIDS Care. 2019;30(2):151–63.PubMedPubMedCentral
67.
Daughtridge GW, Conyngham SC, Ramirez N, Koenig HC. I am men's health: generating adherence to HIV pre-exposure prophylaxis (PrEP) in young men of color who have sex with men. J Int Assoc Provid AIDS Care. 2015;14(2):103–7.PubMed
68.
Rao WW, Yang MJ, Cao BN, et al. Psychological distress in cancer patients in a large Chinese cross-sectional study. J Affect Disord. 2019;245:950–6.PubMed
69.
Ronel J, Dinkel A, Wolf E, et al. Anxiety, depression, and health-related quality of life in aging people living with HIV compared to diabetes patients and patients with minor health conditions: a longitudinal study. Psychol Health Med. 2018;23(7):823–30.PubMed
70.
Fields E, Morgan A, Sanders RA. The intersection of sociocultural factors and health-related behavior in Lesbian, Gay, bisexual, and transgender youth: experiences among young black gay males as an example. Pediatr Clin N Am. 2016;63(6):1091–106.
71.
Wilson PA, Meyer IH, Antebi-Gruszka N, Boone MR, Cook SH, Cherenack EM. Profiles of resilience and psychosocial outcomes among young black gay and bisexual men. Am J Commun Psychol. 2016;57(1–2):144–57.
72.
Lane SD, Rubinstein RA, Bergen-Cico D, et al. Neighborhood trauma due to violence: a multilevel analysis. J Health Care Poor Underserved. 2017;28(1):446–62.PubMed
73.
Meyer IH, Northridge ME. The health of sexual minorities: public health perspectives on lesbian, gay, bisexual and transgender populations. New York: Springer; 2007.
74.
Mustanski B, Garofalo R, Herrick A, Donenberg G. Psychosocial health problems increase risk for HIV among urban young men who have sex with men: preliminary evidence of a syndemic in need of attention. Ann Behav Med. 2007;34(1):37–45.PubMedPubMedCentral
75.
Stall R, Mills TC, Williamson J, et al. Association of co-occurring psychosocial health problems and increased vulnerability to HIV/AIDS among urban men who have sex with men. Am J Public Health. 2003;93(6):939–42.PubMedPubMedCentral
76.
Young LE, Schumm P, Alon L, et al. PrEP Chicago: a randomized controlled peer change agent intervention to promote the adoption of pre-exposure prophylaxis for HIV prevention among young Black men who have sex with men. Clin Trials. 2018;15(1):44–52.PubMed
77.
Duncan DT, Hickson DA, Goedel WC, et al. The social context of HIV prevention and care among black men who have sex with men in three U.S. Cities: the neighborhoods and networks (N2) cohort study. Int J Environ Res Public Health. 2019;16(11):1922.PubMedCentral
78.
Phillips G 2nd, Neray B, Birkett M, Felt D, Janulis P, Mustanski B. Role of social and sexual network factors in PrEP utilization among YMSM and transgender women in Chicago. Prev Sci. 2019;20(7):1089–97.PubMedPubMedCentral
79.
Haberer JE, Kidoguchi L, Heffron R, et al. Alignment of adherence and risk for HIV acquisition in a demonstration project of pre-exposure prophylaxis among HIV serodiscordant couples in Kenya and Uganda: a prospective analysis of prevention-effective adherence. J Int AIDS Soc. 2017;20(1):21842.PubMedPubMedCentral
80.
Baeten J, Palanee-Phillips T, Mgodi N, et al. High uptake and reduced HIV-1 incidence in an open-lable trial of the dapivirine ring. Conference on Retroviruses and Opportunistic Infections; Bsoton, MA. abs 143LB. 2018.
81.
Derby N, Lal M, Aravantinou M, et al. Griffithsin/Carrageenan inserts prevent SHIV, HSV-2, and HPV infections in vivo. Conference on Retroviruses and Opportunistic Infections; Boston, MA. abs 84. 2018.
82.
Myers JE, Sepkowitz KA. A pill for HIV prevention: deja vu all over again? Clin Infect Dis. 2013;56(11):1604–12.PubMed
83.
Link BG, Phelan J. Social conditions as fundamental causes of disease. J Health Soc Behav. 1995;Spec No:80–94.
84.
Rael CT, Martinez M, Giguere R, et al. Barriers and facilitators to oral PrEP use among transgender women in New York City. AIDS Behav. 2018;22(11):3627–36.PubMedPubMedCentral
85.
Eaton LA, Kalichman SC, Price D, Finneran S, Allen A, Maksut J. Stigma and conspiracy beliefs related to pre-exposure prophylaxis (PrEP) and interest in using PrEP among black and white men and transgender women who have sex with men. AIDS Behav. 2017;21(5):1236–46.PubMedPubMedCentral
86.
Mustanski B, Ryan DT, Hayford C, Phillips G 2nd, Newcomb ME, Smith JD. Geographic and individual associations with PrEP stigma: results from the RADAR cohort of diverse young men who have sex with men and transgender women. AIDS Behav. 2018;22(9):3044–56.PubMedPubMedCentral
87.
Golub SA, Kowalczyk W, Weinberger CL, Parsons JT. Preexposure prophylaxis and predicted condom use among high-risk men who have sex with men. J Acquir Immune Defic Syndr. 2010;54(5):548–55.PubMedPubMedCentral
Metadata
Title
Adherence to Pre-exposure Prophylaxis in Black Men Who Have Sex with Men and Transgender Women in a Community Setting in Harlem, NY
Authors
P. W. Colson
J. Franks
Y. Wu
F. S. Winterhalter
J. Knox
H. Ortega
W. M. El-Sadr
Y. Hirsch-Moverman
Publication date
01-12-2020
Publisher
Springer US
Published in
AIDS and Behavior / Issue 12/2020
Print ISSN: 1090-7165
Electronic ISSN: 1573-3254
DOI
https://doi.org/10.1007/s10461-020-02901-6

Other articles of this Issue 12/2020

AIDS and Behavior 12/2020 Go to the issue

Notes From The Field

Learning from People with HIV: Their Insights are Critical to Our Response to the Intersecting COVID-19 and HIV Pandemics in Africa

Original Paper

“It’s Like Plan B but for HIV!” Design and Evaluation of a Media Campaign to Drive Demand for PEP

Guest Editorial

Not Remembering History, Dooms Us to Repeat It: Using the Lessons of the Global HIV Response to Address COVID-19

Notes From The Field

AIDS Activism and Coronavirus Vaccine Challenge Trials

Substantive Review

Systematic Review of Interventions to Reduce HIV Risk Among Men Who Purchase Sex in Low- and Middle-Income Countries: Outcomes, Lessons Learned, and Opportunities for Future Interventions

Original Paper

Antiretroviral Adherence, Drug Resistance, and the Impact of Social Determinants of Health in HIV-1 Patients in the US

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits